Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure
NCT ID: NCT03741972
Last Updated: 2022-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2018-12-21
2022-04-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF
NCT04739215
Sodium Glucose Cotransporter-2 Inhibitors and Salt-sensitivity in Type 2 Diabetes
NCT06007157
Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes
NCT04203927
Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes
NCT05194592
Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes
NCT02397421
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
Patients with diabetes and heart failure that are treated with iSGLT2
iSGTL2
Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
iSGTL2
Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c\> 6.5%
* Estimated GF\> 45 ml / min
* BMI: ≥25 Kg / m2
* Stable pharmacological treatment of Heart Failure in the last 3 months
Exclusion Criteria
* DM2 with C-peptide \<1 ng / mL
* GEF \<45 ml / min
* Recurrent urinary tract infections
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Germans Trias i Pujol Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antoni Bayés Genís
Chief of the Cardiology Unit
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nuria Alonso Pedrol
Role: PRINCIPAL_INVESTIGATOR
Germans Trias i Pujol Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Germans Trias i Pujol University Hospital
Badalona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICO-2018-03-PA-Glucosur
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.